AAPL297.01-1.00 (-0.34%) ▼|ABBV230.01+13.52 (+6.25%) ▲|ABT87.83-0.58 (-0.66%) ▼|ACN124.83-3.15 (-2.46%) ▼|ADBE194.90-0.26 (-0.13%) ▼|AMAT640.18+23.07 (+3.74%) ▲|AMD551.63+14.26 (+2.65%) ▲|AMGN344.72+7.12 (+2.11%) ▲|AMT176.43+0.38 (+0.22%) ▲|AMZN232.79-11.60 (-4.75%) ▼|AVGO392.13-19.22 (-4.67%) ▼|AXP338.07+0.07 (+0.02%) ▲|BA220.83-1.89 (-0.85%) ▼|BAC57.37+1.17 (+2.08%) ▲|BKNG167.77-4.01 (-2.33%) ▼|BLK1,051.74+1.65 (+0.16%) ▲|BMY54.70+0.70 (+1.30%) ▲|BNY146.44+2.81 (+1.96%) ▲|BRK-B488.69-0.77 (-0.16%) ▼|C145.67+2.61 (+1.82%) ▲|CAT1,022.28+36.46 (+3.70%) ▲|CL88.67-0.81 (-0.91%) ▼|CMCSA22.32-0.11 (-0.49%) ▼|COF200.70-0.83 (-0.41%) ▼|COP109.70+1.96 (+1.82%) ▲|COST951.35-0.10 (-0.01%) ▼|CRM150.12-1.66 (-1.09%) ▼|CSCO121.53+1.99 (+1.66%) ▲|CVS101.30+2.98 (+3.03%) ▲|CVX175.06+1.43 (+0.82%) ▲|DE598.59+9.35 (+1.59%) ▲|DHR178.19+1.02 (+0.58%) ▲|DIS102.45-1.44 (-1.39%) ▼|DUK123.52-0.34 (-0.27%) ▼|EMR150.21-0.45 (-0.30%) ▼|FDX328.78+3.80 (+1.17%) ▲|GD343.36-6.65 (-1.90%) ▼|GE355.12-2.52 (-0.70%) ▼|GEV1,127.59+17.86 (+1.61%) ▲|GILD124.87+1.11 (+0.90%) ▲|GM80.43+1.14 (+1.44%) ▲|GOOG348.78-18.68 (-5.08%) ▼|GOOGL349.68-18.35 (-4.99%) ▼|GS1,106.37+9.81 (+0.89%) ▲|HD326.62-7.66 (-2.29%) ▼|HON228.11-0.90 (-0.39%) ▼|IBM252.22+3.12 (+1.25%) ▲|INTC140.94+6.95 (+5.19%) ▲|INTU257.77-9.23 (-3.46%) ▼|ISRG402.95-3.83 (-0.94%) ▼|JNJ231.29+2.90 (+1.27%) ▲|JPM331.48+6.26 (+1.92%) ▲|KO79.53+0.14 (+0.18%) ▲|LIN516.71+4.56 (+0.89%) ▲|LLY1,102.08+3.51 (+0.32%) ▲|LMT493.60-17.35 (-3.40%) ▼|LOW214.40-7.80 (-3.51%) ▼|LRCX409.54+20.50 (+5.27%) ▲|MA484.09-5.70 (-1.16%) ▼|MCD270.10-8.51 (-3.05%) ▼|MDLZ59.51-0.61 (-1.01%) ▼|MDT79.27-0.07 (-0.09%) ▼|META563.85-13.37 (-2.32%) ▼|MMM163.22+2.62 (+1.63%) ▲|MO69.51+0.39 (+0.56%) ▲|MRK115.48+1.61 (+1.41%) ▲|MS227.09+3.92 (+1.76%) ▲|MSFT367.34-12.06 (-3.18%) ▼|MU1,211.38+77.39 (+6.82%) ▲|NEE86.08-0.67 (-0.77%) ▼|NFLX72.88-4.50 (-5.82%) ▼|NKE43.19-2.01 (-4.45%) ▼|NOW93.01-2.03 (-2.14%) ▼|NVDA208.65-2.04 (-0.97%) ▼|ORCL175.07-9.22 (-5.00%) ▼|PEP140.71-1.31 (-0.92%) ▼|PFE25.08-0.13 (-0.52%) ▼|PG147.68-2.70 (-1.80%) ▼|PLTR119.50-8.97 (-6.98%) ▼|PM173.17-5.23 (-2.93%) ▼|QCOM221.90-4.21 (-1.86%) ▼|RTX181.83-3.77 (-2.03%) ▼|SBUX100.15-0.50 (-0.50%) ▼|SCHW92.03+0.33 (+0.36%) ▲|SO93.43+0.34 (+0.37%) ▲|SPG214.57+3.24 (+1.53%) ▲|T22.10+0.09 (+0.41%) ▲|TMO464.01-0.60 (-0.13%) ▼|TMUS180.06-1.61 (-0.89%) ▼|TSLA405.05+4.56 (+1.14%) ▲|TXN332.28+9.42 (+2.92%) ▲|UBER71.43-0.21 (-0.29%) ▼|UNH406.68+5.72 (+1.43%) ▲|UNP259.91+3.03 (+1.18%) ▲|UPS107.24+2.38 (+2.27%) ▲|USB58.68+0.54 (+0.93%) ▲|V326.60-0.64 (-0.20%) ▼|VZ45.36-0.01 (-0.02%) ▼|WFC83.84+1.64 (+2.00%) ▲|WMT117.18+0.00 (+0.00%) ▲|XOM138.47+0.66 (+0.48%) ▲|AAPL297.01-1.00 (-0.34%) ▼|ABBV230.01+13.52 (+6.25%) ▲|ABT87.83-0.58 (-0.66%) ▼|ACN124.83-3.15 (-2.46%) ▼|ADBE194.90-0.26 (-0.13%) ▼|AMAT640.18+23.07 (+3.74%) ▲|AMD551.63+14.26 (+2.65%) ▲|AMGN344.72+7.12 (+2.11%) ▲|AMT176.43+0.38 (+0.22%) ▲|AMZN232.79-11.60 (-4.75%) ▼|AVGO392.13-19.22 (-4.67%) ▼|AXP338.07+0.07 (+0.02%) ▲|BA220.83-1.89 (-0.85%) ▼|BAC57.37+1.17 (+2.08%) ▲|BKNG167.77-4.01 (-2.33%) ▼|BLK1,051.74+1.65 (+0.16%) ▲|BMY54.70+0.70 (+1.30%) ▲|BNY146.44+2.81 (+1.96%) ▲|BRK-B488.69-0.77 (-0.16%) ▼|C145.67+2.61 (+1.82%) ▲|CAT1,022.28+36.46 (+3.70%) ▲|CL88.67-0.81 (-0.91%) ▼|CMCSA22.32-0.11 (-0.49%) ▼|COF200.70-0.83 (-0.41%) ▼|COP109.70+1.96 (+1.82%) ▲|COST951.35-0.10 (-0.01%) ▼|CRM150.12-1.66 (-1.09%) ▼|CSCO121.53+1.99 (+1.66%) ▲|CVS101.30+2.98 (+3.03%) ▲|CVX175.06+1.43 (+0.82%) ▲|DE598.59+9.35 (+1.59%) ▲|DHR178.19+1.02 (+0.58%) ▲|DIS102.45-1.44 (-1.39%) ▼|DUK123.52-0.34 (-0.27%) ▼|EMR150.21-0.45 (-0.30%) ▼|FDX328.78+3.80 (+1.17%) ▲|GD343.36-6.65 (-1.90%) ▼|GE355.12-2.52 (-0.70%) ▼|GEV1,127.59+17.86 (+1.61%) ▲|GILD124.87+1.11 (+0.90%) ▲|GM80.43+1.14 (+1.44%) ▲|GOOG348.78-18.68 (-5.08%) ▼|GOOGL349.68-18.35 (-4.99%) ▼|GS1,106.37+9.81 (+0.89%) ▲|HD326.62-7.66 (-2.29%) ▼|HON228.11-0.90 (-0.39%) ▼|IBM252.22+3.12 (+1.25%) ▲|INTC140.94+6.95 (+5.19%) ▲|INTU257.77-9.23 (-3.46%) ▼|ISRG402.95-3.83 (-0.94%) ▼|JNJ231.29+2.90 (+1.27%) ▲|JPM331.48+6.26 (+1.92%) ▲|KO79.53+0.14 (+0.18%) ▲|LIN516.71+4.56 (+0.89%) ▲|LLY1,102.08+3.51 (+0.32%) ▲|LMT493.60-17.35 (-3.40%) ▼|LOW214.40-7.80 (-3.51%) ▼|LRCX409.54+20.50 (+5.27%) ▲|MA484.09-5.70 (-1.16%) ▼|MCD270.10-8.51 (-3.05%) ▼|MDLZ59.51-0.61 (-1.01%) ▼|MDT79.27-0.07 (-0.09%) ▼|META563.85-13.37 (-2.32%) ▼|MMM163.22+2.62 (+1.63%) ▲|MO69.51+0.39 (+0.56%) ▲|MRK115.48+1.61 (+1.41%) ▲|MS227.09+3.92 (+1.76%) ▲|MSFT367.34-12.06 (-3.18%) ▼|MU1,211.38+77.39 (+6.82%) ▲|NEE86.08-0.67 (-0.77%) ▼|NFLX72.88-4.50 (-5.82%) ▼|NKE43.19-2.01 (-4.45%) ▼|NOW93.01-2.03 (-2.14%) ▼|NVDA208.65-2.04 (-0.97%) ▼|ORCL175.07-9.22 (-5.00%) ▼|PEP140.71-1.31 (-0.92%) ▼|PFE25.08-0.13 (-0.52%) ▼|PG147.68-2.70 (-1.80%) ▼|PLTR119.50-8.97 (-6.98%) ▼|PM173.17-5.23 (-2.93%) ▼|QCOM221.90-4.21 (-1.86%) ▼|RTX181.83-3.77 (-2.03%) ▼|SBUX100.15-0.50 (-0.50%) ▼|SCHW92.03+0.33 (+0.36%) ▲|SO93.43+0.34 (+0.37%) ▲|SPG214.57+3.24 (+1.53%) ▲|T22.10+0.09 (+0.41%) ▲|TMO464.01-0.60 (-0.13%) ▼|TMUS180.06-1.61 (-0.89%) ▼|TSLA405.05+4.56 (+1.14%) ▲|TXN332.28+9.42 (+2.92%) ▲|UBER71.43-0.21 (-0.29%) ▼|UNH406.68+5.72 (+1.43%) ▲|UNP259.91+3.03 (+1.18%) ▲|UPS107.24+2.38 (+2.27%) ▲|USB58.68+0.54 (+0.93%) ▲|V326.60-0.64 (-0.20%) ▼|VZ45.36-0.01 (-0.02%) ▼|WFC83.84+1.64 (+2.00%) ▲|WMT117.18+0.00 (+0.00%) ▲|XOM138.47+0.66 (+0.48%) ▲|
20.7 C
New York
Tuesday, June 23, 2026

Tag: pharmaceutical

newssourceFORcompanyinformationcontent1marketreleases

Avicanna Announces Closing of Non-Brokered Private Placement

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS

Quetzal Therapeutics Debuts with Expert Leadership, High-Impact Pipeline and $50 Million of Committed Capital

Quetzal Therapeutics, a newly formed biopharmaceutical company, announced its official launch today with $50 million of committed capital.

Senior Living Members Set to Receive Even Greater Value as Navigator Group Purchasing, Inc. Extends Strategic Partnership with Foodbuy

PARSIPPANY, N.J., July 16, 2025 /PRNewswire/ -- Navigator Group Purchasing, Inc., a Managed Health Care Associates, Inc. (MHA) Company, and the largest and most experienced...

RxPreferred Launches My-RxP: Cutting Costs for Brand, Specialty, GLP-1, and Fertility Medications by Up to 60%

NASHVILLE, Tenn., July 16, 2025 /PRNewswire/ -- RxPreferred, a leading transparent pharmacy benefit administrator, is proud to announce the launch of My-RxP, an innovative medication...

Leading Drug Delivery Conference PODD Announces its 15th Annual Agenda

The Conference Forum announces the 15th annual PODD Drug Delivery Conference's 2025 agenda and featured sessions. NEW YORK, July 16, 2025 /PRNewswire/ -- Today, PODD: Partnership...

Safi Biotherapeutics and Functional Fluidics Initiate Collaboration to Validate Health and Quality of Manufactured RBCs

Collaboration to support Safi IND data package for use of mRBCs in sickle cell disease chronic transfusions CAMBRIDGE, Mass. and DETROIT, July 16, 2025 /PRNewswire/...

WuXi Biologics Granted Highest Negligible-Risk ESG Rating from Morningstar Sustainalytics

Best ESG rating tier of negligible-risk with a top 1% global ranking scoreIndustry and Regional ESG Top-Rated Company for five consecutive yearsLeader in Green...

TFS HealthScience Strengthens Global Ophthalmology Unit with Strategic Hires and Integrated Delivery Model

LUND, Sweden, July 16, 2025 /PRNewswire/ -- TFS HealthScience (TFS), a leading global Contract Research Organization (CRO), is expanding its ophthalmology business unit with...

TFS HealthScience Strengthens Global Ophthalmology Unit with Strategic Hires and Integrated Delivery Model

LUND, Sweden, July 16, 2025 /PRNewswire/ -- TFS HealthScience (TFS), a leading global Contract Research Organization (CRO), is expanding its ophthalmology business unit with...

[Latest] Global Ultomiris Drug Market Size/Share Worth USD 64.12 Billion by 2034 at a 31.52% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends,...

[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Ultomiris Drug Market size & share revenue was valued at approximately USD 4.16 Billion in 2024 and is expected to reach USD 5.47 Billion in 2025 and is expected to reach around USD 64.12 Billion by 2034, at a CAGR of 31.52% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are AstraZeneca, Xencor, Inc., Chugai Pharmaceutical, Argenx, Alexion Pharmaceuticals, and others. 
[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Ultomiris Drug Market size & share revenue was valued at approximately USD 4.16 Billion in 2024 and is expected to reach USD 5.47 Billion in 2025 and is expected to reach around USD 64.12 Billion by 2034, at a CAGR of 31.52% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are AstraZeneca, Xencor, Inc., Chugai Pharmaceutical, Argenx, Alexion Pharmaceuticals, and others.

Akeso Announces First Patient Enrolled in the Phase III Trial（AK112-312/HARMONi-GI6）of Ivonescimab for First-Line Treatment of Advanced Metastatic Colorectal Cancer

HONG KONG, July 15, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the first patient has been successfully...

ArkBio’s Ziresovir Included into Pediatric RSV Drug Priority List by WHO

SHANGHAI, July 16, 2025 /PRNewswire/ -- In the newly released "Paediatric drug optimization for respiratory syncytial virus (PADO-RSV) meeting report" by Global Accelerator for...

ArkBio’s Ziresovir Included into Pediatric RSV Drug Priority List by WHO

SHANGHAI, July 16, 2025 /PRNewswire/ -- In the newly released "Paediatric drug optimization for respiratory syncytial virus (PADO-RSV) meeting report" by Global Accelerator for...

ArkBio’s Ziresovir Included into Pediatric RSV Drug Priority List by WHO

SHANGHAI, July 15, 2025 /PRNewswire/ -- In the newly released "Paediatric drug optimization for respiratory syncytial virus (PADO-RSV) meeting report" by Global Accelerator for...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsPharmaceutical

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers